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Abstract 13 
Nanoparticles (NPs) are instantly modified once injected in the bloodstream because of their 14 
interaction with the blood components. The spontaneous coating of NPs by proteins, once in 15 
contact with biological fluids, has been termed the ‘protein corona’ and it is considered to be 16 
a determinant factor for the pharmacological, toxicological and therapeutic profile of NPs. 17 
Protein exposure time is thought to greatly influence the composition of protein corona, 18 
however the dynamics of protein interactions under realistic, in vivo conditions remain 19 
unexplored. The aim of this study was to quantitatively and qualitatively investigate the time 20 
evolution of in vivo protein corona, formed onto blood circulating, clinically used, PEGylated 21 
liposomal doxorubicin. Protein adsorption profiles were determined 10 min, 1h and 3h post-22 
injection of liposomes into CD-1 mice. The results demonstrated that a complex protein 23 
corona was formed as early as 10 min post-injection. Even though the total amount of 24 
protein adsorbed did not significantly change over time, the fluctuation of protein 25 
abundances observed indicated highly dynamic protein binding kinetics. 26 
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Highly dynamic binding kinetics of in vivo protein corona, formed onto PEGylated liposomal 49 
doxorubicin nanoparticles after intravenous administration 50 
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Introduction 67 
Nanoparticles (NPs) are thought to be instantly modified once injected in the bloodstream 68 
because of their tendency to interact with the surrounding blood constituents, of which proteins have 69 
been mostly studied today. The adsorption of proteins and their layering onto the surface of NPs has 70 
been termed the ‘protein corona’.1 This bio-transformation of nanomaterials has been postulated as a 71 
determinant factor for their overall biological behaviour and eventually their therapeutic efficacy.  72 
The encapsulation of chemotherapeutic agents into phospholipid-based nanoscale vesicles, 73 
called liposomes, has been the most clinically established strategy to reduce the toxicity to normal 74 
tissues and simultaneously increase their accumulation into highly vascularised solid tumors.2, 3 75 
Liposomal nanocarriers are being clinically used for more than 20 years, yet the effect of ‘protein 76 
corona’ formation on liposomal pharmacology is scarcely studied and far from being well understood. 77 
Despite the clinical use of liposomal doxorubicin (Doxil®) 4 and the increased interest in the study of 78 
serum protein corona formation around nanoparticles, there is currently no report in the literature 79 
describing the identification of proteins adsorbed onto blood circulating doxorubicin-encapsulated 80 
PEGylated liposomes. Such knowledge is needed not only to understand and predict liposomal 81 
pharmacology, but also to improve the existing, clinically-used formulations, often displaying relatively 82 
compromised therapeutic efficacy. The high-throughput proteomics analysis methods available today 83 
are powerful tools to comprehensively study protein corona profiles of clinically used nanoparticles. 84 
In addition to the physiochemical characteristics of NPs, protein exposure time is thought to 85 
be a critical factor that shapes the composition of protein corona. The dynamics of protein interactions 86 
with macroscale surfaces was first described by Vroman in 1962,5 suggesting a time-dependent 87 
association and dissociation of proteins. According to this model, highly abundant proteins, 88 
dominating at the early stage are later replaced by less abundant proteins with higher affinity for the 89 
surface. This description, referred to as the ‘Vroman effect’, shaped the hypothesis that protein 90 
corona formed onto the large surface area of NPs is a dynamic entity that evolves with time. There 91 
have been several in vitro investigations into the time evolution of protein corona.6-8 Time-resolved 92 
characterisation of in vitro protein corona was recently comprehensively investigated for silica and 93 
polystyrene nanoparticles after the incubation with human plasma. In addition to ‘Vroman’ defined 94 
binding kinetics, authors described the existence of more complex, ‘peak’ or ‘cup’ shaped binding 95 
kinetics 7. Despite the high-resolution quantitative LC-MS based proteomics employed and the insight 96 
offered 7, the limitation of these studies lies on the in vitro design of the interaction that fails to 97 
recognize the highly dynamic nature of blood and its heterogeneous flow velocity.  98 
In a recent report,9 we described a protocol to investigate the in vivo protein corona forming 99 
onto three different types of blood circulating liposome types (bare, PEGylated and targeted). The 100 
formation of in vivo protein corona was determined after the recovery of the liposomes from the blood 101 
circulation of CD-1 mice 10 min post-injection, whereas in vitro protein corona was determined after 102 
the incubation of liposomes in CD-1 mouse plasma. The differences between the protein coronas that 103 
formed in vitro and in vivo were revealed for the first time. The molecular complexity and morphology 104 
of the in vivo protein corona was shown not to be adequately predicted by the in vitro plasma 105 
incubation of NPs. Even though the total amount of protein attached on circulating liposomes 106 
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correlated with that observed from in vitro incubations, the variety of molecular species in the in vivo 107 
corona was considerably wider. However, one of the limitations of that study was that the liposome 108 
systems studied (even though all constituted vesicles that have been clinically trialed) did not 109 
encapsulate any therapeutic agent. In addition, due to the short half-life of bare (non-PEGylated) 110 
liposomes employed, we chose to investigate corona formation at a single time point (10 min post-111 
incubation).  112 
In this study, we attempted to investigate the time evolution of protein corona under realistic in 113 
vivo conditions. Given the lack of protein corona investigations for clinically used liposomes, we 114 
employed PEGylated liposomal doxorubicin, identical to the clinical product intravenously infused in 115 
patients. The drug-loaded vesicles were injected into CD1 mice and recovered from the blood 116 
circulation 10min, 1h and 3h post-injection. The protein coronas formed at these three different time 117 
points were qualitatively and quantitatively characterized and compared (Figure 1). 118 
 119 
Results and Discussion 120 
The chemical composition and the physicochemical characteristics of doxorubicin-121 
encapsulated PEGylated liposomes that were fabricated for this study are summarized in Table S1. 122 
The lipid composition and molar ratios of the individual lipid bilayer components were chosen to 123 
match the exact liposome composition of the clinically-used liposomal doxorubicin agent Doxil®. 124 
Dynamic light scattering (DLS), ζ-potential measurements and negative stain transmission electron 125 
microscopy (TEM) were performed prior to intravenous administration of liposomes to access their 126 
properties and morphology. Liposomes had a mean hydrodynamic diameter of 115 nm, a negative 127 
surface charge of -36mV and displayed low polydispersity values (<0.06) indicating a narrow size 128 
distribution (Figure 2A). TEM imaging showed well-dispersed, round shaped vesicles, with their size 129 
correlating that of DLS measurements (Figure 2B; Figure 2C). 130 
To obtain a time-dependent investigation of the in vivo formed protein corona, liposomes were 131 
intravenously administered via tail vein injection into CD-1 mice and recovered by cardiac puncture 132 
10min, 1h and 3h post-injection, as shown in Figure 1. Plasma was then prepared from recovered 133 
blood by centrifugation (see Experimental section for further details). A protocol combining size 134 
exclusion chromatography and membrane ultrafiltration was used for the isolation of liposome-corona 135 
complexes from unbound and loosely bound plasma proteins, as previously described.9 This protocol 136 
allows only the retention of the tightly adsorbed proteins onto the liposome surface, also referred by 137 
some as the ‘hard corona’.10  138 
Dynamic light scattering measurements of protein corona-coated liposomes demonstrated 139 
that their size distribution broadened (larger polydispersity index), while their surface charge remained 140 
negative (Figure 2A; Table S1). In agreement with previous studies investigating liposomal protein 141 
corona formation, we observed a blood-induced reduction in the mean diameter of liposomes, 142 
consistent with all different time points of investigation (Figure 2A; Table S1).9, 11 This osmotically-143 
driven shrinkage was attributed to the high elastic deformation of liposomes, however it was also 144 
observed here for doxorubicin-loaded vesicles without content loss as evidenced by cryo-EM (Figure 145 
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2C). In addition, TEM revealed well-dispersed liposomes that retained their structural integrity after 146 
recovery, while the presence of the protein molecules adsorbed onto their surface revealed protein 147 
corona formation, as early as 10 min-post injection (Figure 2B and FigureS1). In agreement with our 148 
previous cryo-EM studies, the in vivo protein corona did not appear to coat all the available liposome 149 
surfaces entirely9 (Figure 2C).            150 
Based on established pharmacokinetic data for the clinically-used PEGylated liposomes 151 
encapsulating doxorubicin,12-15 we knew that 40% of injected dose will remain in circulation for at least 152 
6 hours. As a first step towards elucidation of the time evolution of the protein corona we 153 
quantitatively compared the coronas formed around the drug-encapsulated PEGylated vesicles at 154 
three different exposure times. To compare the total amount of protein adsorbed, we calculated the 155 
protein binding ability (Pb), defined as the amount of protein associated with each µmole of lipid. As 156 
shown in Figure 3A, Pb values determined at the earliest exposure time (t=10min) did not 157 
significantly change even after the longest blood exposure time (t=3h). This data indicated that 158 
liposome-specific protein fingerprints were already established by the earliest time point (t=10min) 159 
and any possible qualitative changes in the composition of protein corona over time would be a result 160 
of a competitive exchange process. Pb values observed for doxorubicin encapsulated liposomes, 161 
were slightly higher than Pb values determined in our previous study for empty liposomes of the same 162 
composition.9 This could be attributed to the different mass and blood flow dynamics of these vesicles 163 
after the encapsulation of doxorubicin. Whether a second layer of proteins with low adherence, 164 
sometimes termed as ‘soft corona’, exists or not remains to be proven and could not be resolved by 165 
our analytical approach. 166 
A comprehensive identification of proteins associated with liposomes was then performed by 167 
mass spectrometry. The Venn diagram in Figure 3B illustrates the number of common and unique 168 
proteins between the coronas formed after the three different time points of recovery. As already 169 
evident from the quantification of total protein adsorbed (Figure 3A), a complex protein corona was 170 
determined at the earliest time point (t=10 min), with 334 identified proteins (Figure 3B). The majority 171 
of identified proteins (n=180) were common between the three time points. 90 unique proteins were 172 
identified for the 10 min-formed corona, whereas 25 and 35 unique proteins were present in the 173 
coronas of 1hr and 3hr recovered liposomes, respectively. It should be noted that the majority of 174 
unique proteins belonged to the group of low abundance, as revealed by the Relative Protein 175 
Abundance (RPA) values determined for each of the identified proteins. Previous in vitro 176 
investigations suggested that protein corona reaches its final equilibrium 1hr post-incubation of NPs 177 
with plasma proteins.6 Barran-Berdon et al. employed mass spectrometry to show that protein corona, 178 
formed onto cationic liposomes incubated with human plasma, forms rapidly (t=1 min) and stops 179 
evolving 1hr post-incubation.6  Our study demonstrated that the in vivo protein corona continues to 180 
evolve over time, even at 3hr post-injection (Figure 3B). These contradictory results are not 181 
surprising, considering the complexity of the physiological environment, the potential effect of blood 182 
flow dynamics on the in vivo formation of the protein corona, as well as the role of possible NP-183 
triggered immune responses that may cause variations in the blood composition over time.  184 
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Pozzi D et al.,16 have previously showed that the in vitro incubation of empty liposomes with 185 
fetal bovine serum (FBS) under static and flow conditions led to protein coronas of different 186 
composition. Interestingly, dynamic (flow) conditions promoted the extensive adherence of low 187 
molecular weight (MW) proteins, in comparison to incubation under static conditions. To investigate 188 
whether the previous observation applies also under the more realistic, dynamic in vivo conditions of 189 
blood flow, bound proteins were classified according to their molecular mass (Figure 3C). In 190 
agreement with the study by Pozzi et al.,16 there was a tendency towards interaction with low MW 191 
proteins. Plasma proteins with MW< 80 accounted for more than 80 % of the protein coronas formed 192 
10min, 1hr and 3hr post-injection. Notably, a fluctuation in the contribution of each protein group 193 
(classified based on MW) on the corona composition was observed over time. For instance,  ~40% of 194 
associated proteins had a MW<20 at 10 min and 3hr time points, whereas the contribution of this 195 
group was significantly lower 1hr post-injection (~25%), indicating the dynamic character of the in vivo 196 
protein corona (Figure 3C).  197 
To better understand the time evolution of the in vivo protein corona, the relative protein 198 
abundance (RPA) of each identified protein was determined. Figure 4A summarizes the 20 most 199 
abundant proteins associated with the surface of liposomes 10 min, 1hr and 3hr after their 200 
intravenous administration. Blood exposure time was found to be a significant factor influencing 201 
liposome-bound protein abundance. Common proteins observed in the Venn diagram of Figure 3B 202 
were not equally abundant (Figure 4). A striking observation was that the most abundant protein of 203 
the three coronas formed at different time points were not identical. Alpha-2 macroglobulin had the 204 
highest RPA value 10min post-injection, while apolipoprotein E and hemoglobin beta-1 were the most 205 
abundant proteins in the coronas of 1hr and 3hr blood-circulating liposomes, respectively. 206 
Lipoproteins were found to be the most abundant class of proteins, contributing to ~20% of the 10 207 
min-formed protein corona (Figure 4B), followed by immunoglobulins (RPA ~ 15%) and complement 208 
proteins (RPA~ 5%) (Figure 4C; Figure 4D). 209 
 Doxorubicin-encapsulated, PEGylated liposomes, employed in this study, were designed to 210 
have a prolonged blood circulation half-life which enhances their possibility to extravasate through the 211 
leaky tumor vasculature.2 There have been several proposed mechanisms to explain the prolonged 212 
circulation of PEGylated nanovehicles. In agreement with previous reports, this study demonstrated 213 
that PEGylated surfaces are not completely inert and interact with the blood components in vivo.17-19 214 
Even though PEGylation reduced the total amount of proteins adsorbed,9 the presence of opsonins 215 
(complement proteins and immunoglobulins) in their protein coronas (Figure 4) may be thought to 216 
contradict with their long-circulating profile. The concept of ‘dys-opsonization’ has been proposed to 217 
describe the adsorption of proteins that extend the circulation time of liposomes.20 Lipoproteins 218 
identified in this study as the most abundant proteins (Figure 4B), have been suggested to have dys-219 
opsonic activity, possibly explained by their competitive binding with opsonic proteins. Also, the PEG-220 
mediated inhibition of liposome interaction with circulating cells has been suggested, based on 221 
previous in vitro studies reporting reduced internalization of liposomes after PEGylation21. According 222 
to this scenario, the identity of the protein corona seems to have a minor impact on the overall 223 
biodistribution profile of PEGylated liposomes. 224 
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As illustrated in Figure 4D, the in vivo protein coronas formed at the three different time 225 
points, consisted of several key complement cascade proteins, involved in the classical (complement 226 
C1q, C4b), alternative (complement factor h) and lectin (mannan-binding lectin serine protease, 227 
mannose-binding lectin) pathways of activation.22 The impact of complement activation on the 228 
potential adverse effects of liposomes had been valued before the term ‘protein corona’ was 229 
introduced.23 Immediately after intravenous infusion, PEGylated liposomal doxorubicin has been 230 
previously shown to interact with the complement system causing transient and in most of the cases 231 
mild hypersensitive reactions, termed as C-activation related pseudoallergy (CARPA).24, 25 Chanan-232 
Khan et al. reported that 45% of cancer patients (n=29) treated for the first time with Doxil 233 
experienced hypersensitivity reactions associated by complement activation.24 Plasma levels of 234 
protein-s bound C terminal complex (SC5B-9) have been traditionally used as an indicator of 235 
complement activation.24 However, correlations between material properties and complement 236 
activation were difficult to be made without thorough identification of adhered proteins. In vivo protein 237 
corona fingerprinting offers a new tool for molecular investigation of nanoparticle-triggered 238 
complement events and the consequences arising from them and more work would be needed to 239 
explore this further. However, it is also important to appreciate the potential limitations of extrapolating 240 
immune system data from mice to humans.26 241 
To gain some further understanding of the protein binding kinetics occurring in vivo after the 242 
intravenous administration of NPs, we classified the most abundant liposome-bound proteins into 5 243 
groups according to the fluctuation of their normalized protein abundance value over time (Figure 244 
S2). In agreement with the ‘Vroman effect’ theory, some proteins replaced or were replaced by others 245 
exhibiting increased (Figure S2A) or reduced (Figure S2B) binding over time, respectively. For 246 
instance, the abundance of fibrinogen in the protein corona formed 3hr post-injection was 5 times 247 
greater in comparison with the abundance observed for the 10min-formed corona. Tenzer and co-248 
workers were the first to describe the existence of more complex, ‘peak’ or ‘cup’ shaped binding 249 
kinetics after the in vitro incubation of silica and polystyrene NPs with human plasma.7  Similarly, we 250 
observed proteins characterized by low abundance at the beginning of blood circulation (t=10min) and 251 
at later time points (t=3hr), but displaying peak abundance at intermediate time points (t=1hr) (Figure 252 
S2C) or vice versa (Figure S2D). In addition to the above mentioned binding kinetic groups we also 253 
observed proteins that retained their abundance over time (Figure S2E).The sum of all the binding 254 
kinetic processes observed, resulted in a constant total amount of protein on the surface of liposomes 255 
over time (Figure 2A). Such observations are of great importance to comprehensively understand the 256 
overall performance of already clinically established formulations. We have previously shown that 257 
almost 40% and 15% of the injected liposomal doxorubicin remains in the blood after 6 h and 24 h, 258 
respectively.13  This suggests that liposomes extravasate at the tumor tissue at different time points 259 
post-injection. It has been also shown that the drug release profiles,27 as well as the interaction of 260 
liposomes with cells,28, 29 are greatly affected by the proteins adsorbed onto their surfaces. Therefore, 261 
the in vivo, highly dynamic protein binding kinetics, demonstrated in this study, could result in altered 262 
therapeutic efficacy of liposomes over time  263 
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         On a broader context, we propose that understanding the biological impact of in vivo forming 264 
protein corona is crucial for the rational design of new formulations, with improved therapeutic 265 
efficacy. Much work has been done concerning the effect of protein corona on the interaction of NPs 266 
with cells, suggesting that protein adsorption can either facilitate30 or inhibit31 cellular uptake. The 267 
observation that the targeting capabilities of nanoscale constructs are diminished while in blood 268 
circulation because of their interaction with plasma proteins31 has also led to the idea of exploiting the 269 
protein corona in order to direct them to specific target cells. According to this strategy, NPs can be 270 
specifically designed to interact with proteins that will initiate targeted receptor mediated 271 
endocytosis.30 However, a comprehensive characterization of protein corona under physiological 272 
conditions is necessary before exploring its potential exploitation for targeting purposes. Blood flow 273 
dynamics, although a great influential factor for nanoparticle-protein interactions, seem to be largely 274 
ignored in the protein corona literature. In our previous study, we demonstrated that the complexity of 275 
in vivo formed protein corona cannot be adequately predicted by in vitro plasma incubations.9 In 276 
addition, data in this study suggest that in vivo characterization of the protein corona at a single time 277 
point is insufficient to describe the surface modifications that nanoparticles experience in vivo. The 278 
fluctuation in the abundance of each identified protein, observed over time, reveals that the formation 279 
of protein corona in a controlled and predictable manner, as often suggested, is challenging, if not 280 
physiologically unrealistic.  281 
 282 
Conclusion 283 
This is the first study to investigate the time evolution of protein corona under realistic in vivo 284 
conditions. Protein adsorption profiles were determined at three different time points post-injection 285 
(10min, 1hr and 3hr) of PEGylated liposomal doxorubicin, clinically used for the treatment of various 286 
neoplastic conditions. The results demonstrated that a complex protein corona was formed as early 287 
as 10min post-injection. Even though the total amount of protein adsorbed did not significantly 288 
change, the abundance of each protein identified fluctuated over time indicating that competitive 289 
exchange processes were taking place. We anticipate that comprehensive identification of protein 290 
coronas under realistic in vivo conditions for different types of blood-injected pharmacological agents 291 
that lie in the nanoscale is necessary to improve our understanding of their overall clinical 292 
performance. 293 
 294 
 295 
 296 
 297 
 298 
 299 
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Experimental 300 
Materials 301 
Hydrogenated soy phosphatidylcholine (HSPC) , 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-302 
N-[methoxy(polyethylene glycol)-2000 (DSPE-PEG2000) and 1,2-distearoyl-sn-glycero-3-303 
phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (ammonium salt) (Mal-DSPE-304 
PEG2000) were purchased from Avanti Polar Lipids (USA), while doxorubicin hydrochloride, 305 
cholesterol and 4-(2-Hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES) were purchased from 306 
Sigma (UK). 307 
 308 
Preparation of PEGylated liposomal doxorubicin nanoparticles  309 
Liposomes were prepared by thin lipid film hydration method followed by extrusion. Table S1 shows 310 
the liposomal formulation employed, the lipid composition and the molar ratios. Briefly, lipids of 311 
different types were dissolved in chloroform:methanol mixture (4:1) in a total volume of 2 ml, using a 312 
25 ml round bottom flask. Organic solvents were then evaporated using a rotary evaporator (Buchi, 313 
Switzerland) at 40 °C, at 150 rotations /min, 1 h under vacuum. Lipid films were hydrated with 314 
ammonium sulphate 250 mM (pH 8.5) at 60 °C to produce large multilammer liposomes. Small 315 
unilamellar liposomes were then produced by extrusion though 800 nm and 200 nm polycarbonate 316 
filters (Whatman, VWR, UK) 10 times each and  then 15 times through 100 nm and 80 nm extrusion 317 
filters (Whatman, VWR, UK) using a mini-Extruder (Avanti Polar Lipids, Alabaster, AL).  318 
 319 
For DOX loading, the ammonium sulphate gradient method was used. Exchanging the external 320 
unencapsulated ammonium sulphate was performed by gel filtration through Sepharose CL-4B 321 
column (15 cm ×1.5 cm) (Sigma, UK) equilibrated with HBS (pH 7.4). Doxorubicin hydrochloride  was 322 
added to the liposome suspensions at 1:20 DOX:Lipids mass ratio in respect to the original total lipid 323 
concentration. Subsequently, samples were incubated at 60 °C for 1h. After incubation, liposomes 324 
were passed through PD-10 desalting columns (GE Healthcare Life Sciences) to remove any free 325 
DOX. 326 
 327 
Animal experiments  328 
Eight to ten week old female CD1 mice were purchased from Charles River (UK).Animal procedures 329 
were performed in compliance with the UK Home Office Code of Practice for the Housing and Care of 330 
Animals used in Scientific Procedures. Mice were housed in groups of five with free access to water 331 
and kept at temperature of 19-22 °C and relative humidity of 45-65%. Before performing the 332 
procedures, animals where acclimatized to the environment for at least 7 days. 333 
 334 
Protein corona formation after in vivo administration 335 
CD1 mice were anesthetized by inhalation of isoﬂurane and liposomes were administered 336 
intravenously via the lateral tail vein, at a lipid dose of 0.125mM/g body weight to achieve a final 337 
doxorubicin dose of 5mg/kg body weight, used for preclinical studies. 32-34 10 minutes, 1h and 3h post- 338 
injection, blood was recovered by cardiac puncture using K2EDTA coated blood collection tubes.  339 
Approximately 0.5-1ml of blood was recovered from each mouse. Plasma was prepared by inverting 340 
10 times the collection tubes to ensure mixing of blood with EDTA and subsequent centrifugation for 341 
12 minutes at 1300 RCF at 4 °C. Supernatant was collected into Protein LoBind Eppendorf Tubes. 342 
For each time point the plasma samples obtained from three mice were pooled together for a final 343 
plasma volume of 1 ml. Three experimental replicates were performed and therefore 9 mice were 344 
used in total for each time point.  345 
 346 
Separation of corona-coated liposomes from unbound and weakly bound proteins  347 
Liposomes recovered from in vivo experiments were separated form excess plasma proteins by size 348 
exclusion chromatography followed by membrane ultrafiltration, as we have previously described.9 349 
Immediately after the in vivo incubations, 1ml of plasma samples was loaded onto a Sepharose CL-350 
4B (SIGMA-ALDRICH) column (15x1.5cm) equilibrated with HBS. Chromatographic fractions 4,5 and 351 
6  containing liposomes were then pooled together and concentrated to 500 µl by centrifugation using 352 
Vivaspin 6 column (10000 MWCO, Sartorious, Fisher Scientific) at 3000rpm. Vivaspin 500 centrifugal 353 
concentrator (1 000 000 MWCO, Sartorious, Fisher Scientific) was then used at 3000 rpm, to further 354 
concentrate the samples to 100 µl and to ensure separation of protein-coated liposomes from the 355 
remaining large unbound proteins. Liposomes were then washed 3 times with 100 µl HBS to remove 356 
weekly bound proteins.  357 
 358 
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Size and zeta potential measurements using dynamic light scattering (DLS) 359 
Liposome size and surface charge were measured using Zetasizer Nano ZS (Malvern, Instruments, 360 
UK). For size measurement, samples were diluted with distilled water in 1 ml cuvettes. Zeta potential 361 
was measured in disposable Zetasizer cuvettes and sample dilution was performed with distilled 362 
water. Size and zeta potential data were taken in three and five measurements, respectively 363 
 364 
Transmission electron microscopy (TEM)  365 
Liposomes of different compositions were visualized with transmission electron microscopy (FEI 366 
Tecnai 12 BioTwin) before and after their in vivo interaction with plasma proteins. Samples were 367 
diluted to 1 mM lipid concentration, then a drop from each liposome suspension was placed onto a 368 
Carbon Film Mesh Copper Grid (CF400-Cu, Electron Microscopy Science) and the excess 369 
suspension was removed with a filter paper. Staining was performed using aqueous uranyl acetate 370 
solution 1%. 371 
 372 
Cryo-electron microscopy 373 
TEM grids of liposomes were prepared in a FEI Vitrobot using 3µl of sample absorbed to freshly glow-374 
discharged R2/2 Quantifoil grids. Grids were continuously blotted for 4–5 s in a 95% humidity 375 
chamber before plunge-freezing into liquid ethane. Data were then recorded on a Polara F30 FEG 376 
operating at 200 kV on a 4K Gatan Ultrascan CCD (charge-coupled device) in low-dose mode. CD 377 
images were recorded between 0.5 and 5.0µm defocus at a normal magnification of 39,000 x and at 378 
3.5 Å/pixel (1 Å = 0.1 nm) and had a maximum electron dose of <25 electrons/Å2. 379 
 380 
Quantification of adsorbed proteins  381 
Proteins associated with recovered liposomes were quantified by BCA Protein assay kit. Pb values, 382 
expressed as µg of protein/µM lipid were then calculated and represented as the average ± standard 383 
error of three independent experiments. For the BCA assay, a 6-point standard curve was generated 384 
by serial dilutions of BSA in HBS, with the top standard at a concentration of 2µg/ml. BCA reagent A 385 
and B were mixed at a ratio of 50:1 and 200µl of the BCA mixture were dispensed into a 96-well plate, 386 
in duplicates. Then, 25µl of each standard or unknown sample were added per well. The plate was 387 
incubated for 30 minutes at 37°C, after which the absorbance was read at 574nm on a plate reader 388 
(Fluostar Omega). Protein concentrations were calculated according to the standard curve. To 389 
quantify lipid concentration, 20 µl of each samples was mixed with 1ml of chloroform and 500 µl of 390 
Stewart assay reagent in an Eppendorf tube. The samples were vortexed for 20 seconds followed by 391 
1 min of centrifugation at 13 000 RPM. 200 µl of the chloroform phase was transferred to a quartz 392 
cuvette. The optical density was measured on a using Cary 50 Bio Spectrophotometer (Agilent 393 
Technologies) at 485 nm. Lipid concentration was calculated according to a standard curve.  394 
 395 
Mass Spectrometry 396 
Proteins associated with 0.05 µM of liposomes were mixed with Protein Solving Buffer (Fisher 397 
Scientific) for a final volume of 25 µl and boiled for 5 minutes at 90°C. Samples were then loaded in 398 
10% Precise Tris-HEPES Protein Gel (Thermo Scientific). The gel was run for 3-5 minutes 100V, in 399 
50 times diluted Tris-HEPES SDS Buffer (Thermo Scientific). Staining was performed with EZ Blue™ 400 
Gel Staining reagent (Sigma Life Science) overnight followed by washing in distilled water for 2 h. 401 
Bands of interest were excised from the gel and dehydrated using acetonitrile followed by vacuum 402 
centrifugation. Dried gel pieces were reduced with 10 mM dithiothreitol and alkylated with 55 403 
mM iodoacetamide. Gel pieces were then washed alternately with 25 mM ammonium bicarbonate 404 
followed by acetonitrile. This was repeated, and the gel pieces dried by vacuum 405 
centrifugation.  Samples were digested with trypsin overnight at 37°C. 406 
 407 
Digested samples were analysed by LC-MS/MS using an UltiMate® 3000 Rapid Separation LC 408 
(RSLC, Dionex Corporation, Sunnyvale, CA) coupled to Orbitrap Velos Pro (Thermo Fisher 409 
Scientific) mass spectrometer. Peptide mixtures were separated using a gradient from 92% A (0.1% 410 
FA in water) and 8% B (0.1% FA in acetonitrile) to 33% B, in 44 min at 300 nL min-1, using a 250 mm 411 
x 75 µm i.d. 1.7 µM BEH C18, analytical column (Waters). Peptides were selected for fragmentation 412 
automatically by data dependant analysis. Data produced were searched using Mascot (Matrix 413 
Science UK), against the [Uniprot] database with taxonomy of [mouse] selected.  Data were validated 414 
using Scaffold (Proteome Software, Portland, OR).  415 
 416 
The Scaffold software (version 4.3.2, Proteome Software Inc.) was used to validate MS/MS based 417 
peptide and protein identifications and for relative quantification based on spectral counting. Peptide 418 
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identifications were accepted if they could be established at greater than 95.0% probability by the 419 
Peptide Prophet algorithm with Scaffold delta-mass correction. Protein identifications were accepted if 420 
they could be established at greater than 99.0% probability and contained at least 2 identified 421 
peptides. Protein probabilities were assigned by the Protein Prophet algorithm.  Proteins that 422 
contained similar peptides and could not be differentiated based on MS/MS analysis alone were 423 
grouped to satisfy the principles of parsimony. Semi quantitative assessment of the protein amounts 424 
was conducted using normalized spectral countings, NSCs, provided by Scaffold Software. The mean 425 
value of NSCs obtained in the three experimental replicates for each protein was normalized to the 426 
protein MW and expressed as a relative quantity by applying the following equation:17 427 
 428 
where, MWNSCk is the percentage molecular weight normalized NSC for protein k and MW is the 429 
molecular weight in kDa for protein k. This equation takes into consideration the protein size and 430 
evaluates the contribution of each protein reflecting its relative protein abundance (RPA). 431 
 432 
Statistical Analysis  433 
Statistical analysis of the data was performed using IBM SPSS Statistics software. One-way analysis 434 
of variance (ANOVA) followed by the Tukey multiple comparison test were used and p values < 0.05 435 
were considered significant. 436 
 437 
 438 
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Figure Legends  555 
Figure1: Schematic description of the experimental design. To obtain a time-dependent 556 
investigation of the in vivo formed protein corona (PC), liposomes were intravenously administered via 557 
tail vein injection into CD-1 mice(n=3 mice / group; 3 independent experiments replicated)  and 558 
recovered by cardiac puncture 10min, 1h and 3h post-injection. The plasma was then separated from 559 
the recovered blood by centrifugation. In vivo protein-coated liposomes were purified from unbound 560 
proteins and protein coronas formed at these three different time points were qualitatively and 561 
quantitatively characterized and compared. 562 
 563 
Figure 2: The effect of protein corona formation on the physicochemical characteristics and 564 
morphology of liposomes. (A) Mean diameter (nm) and ζ-potential (mV) distributions and (B) 565 
Negative stain TEM imaging of liposomes before their interaction with plasma proteins and 10 min, 566 
1h and 3h after their i.v. injection and recovery from CD-1 mice. (C) Cryo-EM imaging of doxorubicin-567 
encapsulating (white arrow) liposomes before injection and recovered after 10 min in blood 568 
circulation, partially coated with plasma proteins (black arrow). All scale bars are 100nm. 569 
Figure 3: Characterization of in vivo protein corona: (A) Comparison of the total amount of 570 
proteins adsorbed in vivo onto liposomes recovered from CD1 mouse circulation 10 min, 1h and 3h 571 
post-injection. Pb values (µg of protein/µM lipid) represent the average and standard error from three 572 
independent experiments, each using three-six mice; (B) Venn diagrams report the number of unique 573 
proteins identified in the in vivo corona formed 10 min, 1h and 3h post-injection and their respective 574 
overlap; (C) Classification of the corona proteins identified according to their molecular mass. 575 
Figure 4: Time evolution of in vivo protein corona:  (A) Most-abundant proteins (top-20) identified 576 
in the protein corona of PEGylated liposomal doxorubicin 10 min, 1h and 3h post-injection by LC-577 
MS/MS. Relative protein abundance (RPA) values represent the average and standard error from 578 
three independent experiments; (B) The relative percentage of lipoproteins, immunoglobulins and 579 
complement proteins identified in the protein corona 10 min, 1h and 3h post-injection. 580 
 581 
 582 
Supporting Figure Legends 583 
Table S1: The physicochemical characteristics of PEGylated liposomal doxorubicin before and 584 
after extraction from blood circulation. Mean vesicle diameter (nm) and ζ-potential (mV) data from 585 
DLS and surface charge electrophoresis are shown. 586 
FigureS1: Negative stain TEM imaging of liposomes before their interaction with plasma proteins and 587 
10 min, 1h and 3h after their i.v. injection and recovery from CD-1 mice. Arrows show the presence of 588 
proteins around the surface of liposomes. All scale bars are 50nm. 589 
Figure S2: Protein binding kinetics during corona evolution. Relative values were normalized to 590 
the maximum amount (set to 1) across the three time points for each of the top-20 proteins. Corona 591 
proteins were classified into five groups: (A) Proteins displaying increased binding over time; (B) 592 
Proteins displaying reduced binding over time (C) Proteins characterized by low abundance at the 593 
early (t=10min) and late time points (t=3h) and higher abundance at intermediate time point (t=1h); 594 
(D) Proteins characterized by high abundance at the early (t=10min) and late time points (t=3h) and 595 
lower abundance at intermediate time point (t=1h); (E) Proteins with constant abundance over time. 596 
 597 
 598 
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